Aridis Pharmaceuticals is buying Kenta Biotech’s anti-infection treatment products for an undisclosed amount.

The acquisition includes six products to treat infections, such as skin infections or respiratory infections, caused by common pathogens. Aridis is also buying a technology that helps discover naturally occurring protective antibodies generated by the human immune system. Terms of the deal were not disclosed.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.